TOKYO, Mar 31 (Pulse News Wire) – Astellas Pharma Inc. (4503.T) detailed its strategic priorities during the Astellas R&D Day, focusing on advancing its pipeline and enhancing revenue streams through disciplined portfolio management.
The company highlighted key programs such as setidegrasib, which achieved proof-of-concept data in pancreatic cancer and non-small cell lung cancer, with phase III trials expected to begin in 2029 and interim results anticipated in 2028. Astellas also emphasized restructuring its R&D organization to boost productivity and accelerate pipeline growth.
The company plans to prioritize multiple asset creation platforms to support long-term sustainable growth and deliver meaningful value to patients. Additionally, the firm outlined efforts to maximize sales revenues post-patent expiry for products like XTANDI, aiming to contribute to 2030s revenue targets.
During the session, CEO Naoki Okamura and Chief Research and Development Officer Tadayoshi Taniguchi addressed attendees, discussing initiatives aimed at accelerating the delivery of patient value through advanced scientific innovation and organizational transformation.
🟢 Confidence: High AI-translated content.